Skip to main content
. 2020 Aug 26;12(9):810. doi: 10.3390/pharmaceutics12090810

Table 2.

List of amounts, volumes and concentrations used in all experiments.

Experiment FabA Dose 3H-FabA Concentration 1 Albumin Concentration 2
µM mg/L µM mg/L
Formulation of in vivo rabbit study 16.8 1000 20.0 1328
16.8 1000 300 19,920
In vivo rabbit VH Low dose 3 0.57 33 0.67 44
0.57 33 10.0 664
In vitro cynomolgus monkey VH Low dose 0.57 33 0.53 35
0.57 33 50.0 3320
0.57 33 100 6640
0.57 33 250 16,600
High dose 4 5.7 330 0.53 35
5.7 330 50.0 3320
5.7 330 100 6640
5.7 330 250 16,600
In vitro human VH (no eye disease) Low dose 0.57 33 4.22 280
0.57 33 50.0 3320
0.57 33 100 6640
0.57 33 250 16,600
High dose 4 5.7 330 4.22 280
5.7 330 50.0 3320
5.7 330 100 6640
5.7 330 250 16,600
In vitro human VH (PDR) Low dose 0.57 33 10.53 699
0.57 33 50.0 3320

1 Calculated using FabA MW of 59.5 kDa. 2 Calculated using albumin MW of 66.4 kDa. 3 Calculated assuming a rabbit vitreous humor volume of 1.5 mL [13]. 4 10-fold of low dose (0.57 µM 3H-FabA complemented with 5.13 µM unlabeled FabA).